<?xml version="1.0" encoding="UTF-8"?>
<p id="p0060">To achieve the elimination targets, major investments and resourcing are required at both national and global levels. In 2020, though there are encouraging signs of national-level investment and achievements, it is clear that investment globally is substantially below target to achieve hepatitis B elimination by 2030(16). Domestic funding mobilisation through innovative financing sources will be critical to implement the GHSS, as the large-scale global investments by donors for HIV, tuberculosis and malaria are unlikely to occur for viral hepatitis in part due to a flattening of overseas development assistance for health (
 <xref rid="bib17" ref-type="bibr">17</xref>). As the global community battles the health, social and economic effects of the COVID-19 pandemic, competing priorities and opportunity costs of investment in other infectious and chronic disease management programmes is being weighed against immediate needs and careful justification of investment is essential.
</p>
